Literature DB >> 10782696

ORL1 receptor ligands: structure-activity relationships of 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones.

S Röver1, J Wichmann, F Jenck, G Adam, A M Cesura.   

Abstract

We have investigated 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-o nes as ligands for the ORL1 receptor. These unsophisticated, achiral compounds show remarkable affinity for the ORL1 receptor. Optimizing for selectivity we show that the maximum of affinity and selectivity versus the other opioid receptors is achieved for 8-cyclodecyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-o ne 2e and 8-(cis-4-isopropyl-cyclohexyl)-1-phenyl-1,3,8-triaza-spiro[4.5] decan-4-one 2q. The identified compounds (2e, 2q) are more or less equipotent to the natural ligand itself, both in the binding assay and in the functional GTPgammaS assay.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782696     DOI: 10.1016/s0960-894x(00)00111-6

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

1.  Molecular modelling studies on the ORL1-receptor and ORL1-agonists.

Authors:  Britta M Bröer; Marion Gurrath; Hans-Dieter Höltje
Journal:  J Comput Aided Mol Des       Date:  2003-11       Impact factor: 3.686

2.  A Simple Representation of Three-Dimensional Molecular Structure.

Authors:  Seth D Axen; Xi-Ping Huang; Elena L Cáceres; Leo Gendelev; Bryan L Roth; Michael J Keiser
Journal:  J Med Chem       Date:  2017-08-08       Impact factor: 7.446

3.  Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.

Authors:  Nurulain T Zaveri; Faming Jiang; Cris Olsen; Willma E Polgar; Lawrence Toll
Journal:  Bioorg Med Chem Lett       Date:  2013-04-04       Impact factor: 2.823

Review 4.  Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP.

Authors:  Nurulain Zaveri; Faming Jiang; Cris Olsen; Willma Polgar; Lawrence Toll
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

5.  The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.

Authors:  Ling Jong; Nurulain Zaveri; Lawrence Toll
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

6.  Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ.

Authors:  Dirk Faulhammer; Bernd Eschgfäller; Sandra Stark; Petra Burgstaller; Werner Englberger; Jeannette Erfurth; Frank Kleinjung; Johanna Rupp; Sebastian Dan Vulcu; Werner Schröder; Stefan Vonhoff; Hermann Nawrath; Clemens Gillen; Sven Klussmann
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

Review 7.  Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.

Authors:  Nurulain Zaveri
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

Review 8.  Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

Authors:  Jolien De Neve; Thomas M A Barlow; Dirk Tourwé; Frédéric Bihel; Frédéric Simonin; Steven Ballet
Journal:  RSC Med Chem       Date:  2021-04-21

9.  The nociceptin/orphanin FQ receptor system as a target to alleviate cancer-induced bone pain in rats: Model validation and pharmacological evaluation.

Authors:  Sonny H J Sliepen; Johanna Korioth; Thomas Christoph; Thomas M Tzschentke; Marta Diaz-delCastillo; Anne-Marie Heegaard; Kris Rutten
Journal:  Br J Pharmacol       Date:  2020-01-21       Impact factor: 8.739

10.  Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.

Authors:  Pankaj R Daga; Willma E Polgar; Nurulain T Zaveri
Journal:  J Chem Inf Model       Date:  2014-09-17       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.